COMMUNIQUÉS West-GlobeNewswire

Vireo Growth Inc. Announces Issuance of Shares in Connection with Altmore Settlement
17/09/2026
MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform today announced that, in connection [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/09/2026
WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
17/09/2026
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of [...]
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
17/09/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of [...]
MAPS Attends Historic FDA Hearing on Psychedelics
17/09/2026
The FDA's Sept. 14 public hearing on the potential future therapeutic use of psychedelic drugs marks one of the most significant regulatory moments for the field. The FDA is accepting written testimony to its docket, [...]
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
17/09/2026
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A [...]
AVAVA Announces $45 Million Financing Led by Catalio Capital Management to Accelerate Next Phase of Growth
17/09/2026
$30 Million Equity Financing and $15 Million Debt Facility Support Continued Commercial Expansion, Innovation and Global Growth BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- AVAVA, Inc., a medical aesthetics company [...]
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
17/09/2026
Innovative gene therapy offers a new option for children with a rare, progressive neurodevelopmental disease Silver Spring, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today approved [...]
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
17/09/2026
The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development [...]
Virbac : Public release of the Half-Year Financial Report at 30 June 2026
17/09/2026
Virbac : Public release of the Half-Year Financial Report at 30 June 2026 The Group released and filed its 2026 half-year financial report with the French “Autorité des marchés financiers”. The document is also [...]
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2026.
17/09/2026
Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2026. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier [...]
Virbac : Half-Year report 2026
17/09/2026
Please find attached Virbac half-year report 2026 Attachment Half-Yearly Financial Report_2026
Virbac : rapport semestriel 2026
17/09/2026
Veuillez trouver le rapport semestriel Virbac 2026 Pièce jointe Rapport financier semestriel_2026
Ultrahuman Launches HealthEx PowerPlug to Combine Medical Records with Continuous Ultrahuman Ring Data for Always-on Health Awareness
17/09/2026
HealthEx PowerPlug for Ultrahuman Ring enables members to catch missed follow-ups and see their medical records alongside their biomarkers SAN FRANCISCO and NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ultrahuman today [...]
PracticeLink Opens Fall 2026 First Practice Fund Applications
17/09/2026
$2,500 awards support aspiring physicians and advanced practice providers on their journey from training to practice ST. LOUIS and HINTON, West Virginia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- PracticeLink today announced [...]
VIRBAC: A robust adjusted EBIT margin² of 18.8%, driven by solid organic revenue growth of 7.4%
17/09/2026
H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin 2 of 18.8% at CERS: Revenue growth is coming from both segments : companion animal +10.0% and farm animal +6.7% with a strong contribution [...]
VIRBAC: Une marge opérationnelle2 solide de 18,8 %, portée par une croissance soutenue du chiffre d'affaires de +7,4 %
17/09/2026
Le premier semestre 2026 affiche une solide croissance du chiffre d'affaires de +7,4 % et une marge d'EBIT ajusté² de 18,8 % à PCC¹ : La croissance du chiffre d'affaires provient des deux segments : animaux de compagnie [...]
FemPulse Ring Gains CE Mark Certification for the EU
17/09/2026
VIENNA and SAN FRANCISCO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s FemPulse Ring™ has [...]

Pages